Stella T. Chou, MD, is an associate professor of pediatrics and chief, Division of Transfusion Medicine, Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania. She received her medical degree at New York Medical College and completed her residency and fellowship in pediatric hematology/oncology at CHOP. Dr Chou also completed a fellowship in transfusion medicine at the Hospital of the University of Pennsylvania. 

Her research focuses on improving red blood cell matching using innovative tools, with a particular interest in sickle cell disease. Her work has demonstrated that inheritance of variant blood group antigens in patients with sickle cell disease contributes to their high rate of red cell antibody formation. Her research laboratory uses induced pluripotent stem cells and primary human cells to model blood diseases and to examine their underlying pathophysiology. Ongoing work focuses on the genetic matching of red cells and creating customized induced pluripotent stem cells with rare blood group antigen combinations as renewable sources of red blood cell reagents to improve antibody identification and donor red cell matching. Since transfusion therapy remains a critical treatment for hemoglobinopathies, her goal is to identify new approaches to minimize alloimmunization, reduce complications, and improve therapy. 

For her innovative research, she was a recipient of the National Blood Foundation Hall of Fame Award in 2018. She has received numerous other awards and honors, including the National Blood Foundation Young Investigator Scholarship in 2011. Dr Chou is a member of several professional organizations, committees, and panels, including the American Society of Hematology, the American Society of Pediatric Hematology/Oncology, the American Association of Blood Banks, and the Clinical Transfusion Medicine Committee (an AABB committee). She is an associate editor of Hematology: American Society of Hematology Education Program. She has published extensively and is an invited lecturer on sickle cell disease and other related topics.

Michael Rutledge DeBaun, MD, MPH, is an internationally recognized physician-scientist whose advocacy and research have resulted in fundamental advances in the medical care of children and adults with sickle cell disease (SCD) and children with Beckwith Wiedemann syndrome, a cancer predisposition syndrome. He is professor of pediatrics and medicine and vice-chair of clinical and translational research in the Department of Pediatrics, and holds the J.C. Peterson Endowed Chair at Vanderbilt University School of Medicine in Nashville, TN. 

After receiving his degrees from Stanford University, he completed his pediatric residency, served as chief resident, and completed his pediatric hematology-oncology fellowship at St. Louis Children’s Hospital, Washington University School of Medicine. He then completed a 4-year United States Public Health Service Epidemiology fellowship at the National Institutes of Health. During the fellowship, he earned an MPH degree from Johns Hopkins Bloomberg School of Public Health in 2003. Dr DeBaun returned to St. Louis and spent 14 years at Washington University School of Medicine, where he was promoted to professor of pediatrics, biostatistics, and neurology, and was the inaugural Ferring Family Chair in Pediatrics. In 2010, he was recruited to Vanderbilt University School of Medicine, where he founded the Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease. The Center is one of the first in the country to establish a medical home care model for children and adults with SCD in a community health center.

Dr DeBaun was the primary physician author of the Sickle Cell Treatment Act, signed by President Bush into law on October 22, 2004 Title VII, creating regional networks for enhanced services for with SCD. His research efforts in SCD have focused on the clinical epidemiology of acute and chronic lung disease, sequelae of silent and overt strokes, including leading 8 investigator-initiated, controlled stroke trials in North America, Europe, and Africa. Additionally, he was the leader of a multidisciplinary team in Ghana that lowered the death rate of pregnant women with SCD by approximately 90%. He continues to work with the team at Korle-Bu Teaching Hospital in Ghana. His research has expanded to include the clinical history and optimal therapy for recurrent ischemic priapism in men with SCD living in Nigeria and malnutrition in older children with SCD living in Nigeria.

Dr DeBaun is an elected member of the American Society for Clinical Investigation (2006), the Association of American Physicians (2008), and the National Academy of Medicine (2009). He has received numerous awards throughout his career, including the Ernest Beutler Prize and Lecture in Clinical Science from the American Society of Hematology (2014) and the following international mentor awards for his work in Ghana, Nigeria, and the United States: the Maureen Andrew Mentor Award from the Society for Pediatric Research (2017) and the American Society of Hematology Mentor Award (2019). He also received the J.E. Wallace Sterling Lifetime Achievement Award in Medicine (2019) from Stanford University School of Medicine, as well as the Humanism in Medicine Award (2002), the Clinical Teacher of the Year Award (2008), and the Distinguished Faculty Award (2009) from Washington University School of Medicine. 

Julie Kanter, MD, is associate professor in the Division of Hematology and Oncology, director of the Adult Sickle Cell Disease Program, and codirector of the Lifespan Comprehensive Sickle Cell Center at the University of Alabama at Birmingham. 

Dr Kanter is a lifespan hematologist specializing in sickle cell disease (SCD). Her research area is broad and includes access to care, implementation and dissemination of guideline-based SCD therapy, and gene therapy. She has received funding from the National Institutes of Health/the National Heart, Lung, and Blood Institute, the Health Resources & Services Administration, and the Centers for Disease Control and Prevention, and works closely with national partners, including the American Society of Hematology, the Sickle Cell Disease Association of America, Inc, the Centers for Disease Control and Prevention, and the National Institutes of Health, on advocacy and research. She also works with industry and federal partners to develop new treatments for SCD. 

Dr Kanter has authored and coauthored more than 100 articles, book chapters, and abstracts. She hopes to train upcoming physicians and providers in SCD to expand the workforce for treating affected individuals.